Wednesday, 28 November 2018

U.S. FDA approves first biosimilar to Roche's cancer drug Rituxan

The U.S. Food and Drug Administration on Wednesday approved Celltrion Inc's Truxima, making it the first biosimilar to Roche Holding AG's Rituxan available in the United States to treat non-Hodgkin's lymphoma.


from Reuters: Health News https://ift.tt/2RrQjd2

No comments:

Post a Comment